Elizaveta Mikhaylenko

Ms. Elizaveta Mikhaylenko

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2020 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
VCVladimir V. Chrishtop
Vladimir V. Chrishtop
ITIrina K. Tomilova
Irina K. Tomilova
TRTatiana A. Rumyantseva
Tatiana A. Rumyantseva
EMElizaveta Mikhaylenko
Elizaveta Mikhaylenko
MAMarco F. Avila-Rodriguez
Marco F. Avila-Rodriguez
Gjumrakch AlievGjumrakch Aliev
Gjumrakch Aliev

29 September 2023 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Closed access
SSS. Yu. Martsevich S.YU.
S. Yu. Martsevich S.YU.
ANA. R. Navasardyan
A. R. Navasardyan
KLKirill Lobastov
Kirill Lobastov
MMM. V. Mikaelyan
M. V. Mikaelyan
EMElizaveta Mikhaylenko
Elizaveta Mikhaylenko
ODOxana M. Drapkina
Oxana M. Drapkina
Nowadays, the pyramid of evidence is the main model of decision-making for healthcare professionals. According to this concept, data from randomized clinical trials (RCTs) are considered lower in hierarchy than data obtained from systematic reviews (SRs) and meta-analyses (MAs). However, it заменить на:is not established whether it is appropriate to rate large RCTs with hard endpoints lower than SRs and MAs that combine data from smaller RCTs of questionable quality, or even from prospective or retrospective observational studies. It is also important to consider that in addition to assessing the quality of the studies included in the SRs and MAs, it is necessary to assess the accuracy of the SRs and MAs themselves. If not rigorously conducted, they can also contain systematic errors, leading to increased risks of data manipulation. The publication covers the main stages and principles of preparing SRs and MAs, common types of systematic errors that can arise at each stage, and methods to minimize them. We believe that the tools, knowledge, and skills we offer will help practicing doctors and healthcare professionals critically assess the results obtained from SRs and MAs in terms of methodology and the mitigation of potential data manipulation risks.

18 November 2020 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
LVL. B. Vaskova
L. B. Vaskova
MTM. V. Tiapkina
M. V. Tiapkina
EMElizaveta Mikhaylenko
Elizaveta Mikhaylenko
Aim. The study was aimed to perform a comparative retrospective pharmacoepidemiological analysis of antipsychotic drugs (APD) used for inpatient treatment for schizophrenia.Materials and methods. This retrospective pharmacoepidemiological study included 1077 medical records of patients diagnosed with schizophrenia according to ICD-10 (F20.0-F20.8) selected for the analysis on the base of a psychiatric inpatient hospital in Moscow during 2013-2017. The study design included socio-demographic data (sex, age, education, disability, social status) and clinical-economic data (diagnoses, duration of hospitalization), information on the prescription frequency of drugs and dose regimens were analyzed. The consumption volume of APD was estimated using the WHO ATS/DDD methodology.Results and discussion. It was found that women prevailed (55-71%) with the mean age ranging from 42.8±14.1 to 47.4±14.7 (±SD – standard deviation). In the studied sampling, paranoid schizophrenia dominated (≥70%). Over the analyzed 5-year period, the consumption volume of APDs was characterized by alternating declines and rises (from 154.49 to 208.09 NDDD/100 bed-days). The consumption of atypical APDs decreased by 7% and typical APDs increased by 25% compared to the base year (2013), respectively. The most significant changes in the consumption were identified for APDs of prolonged action (a decrease by 67% compared to 2013). Haloperidol and clozapine (oral forms), which are included in the DU90% segment, remained the leaders in terms of prescription frequency and consumption volume (49.04 and 45.26 NDDD/100 bed days in 2017, respectively). Moreover, trihexiphenydil (used to correct adverse reactions) also had a high frequency of administration and consumption.Conclusion. It was found that 1/2 of all prescriptions were antipsychotic drugs used to treat schizophrenia. The total consumption volume of APDs in 2017 decreased by 9.2% compared to 2013. A high consumption volume is typical for drugs from the subgroup of typical APDs, but atypical APDs prevailed in terms of prescription frequency, which may indicate the prescription of typical APDs in doses exceeding the defined daily dose.

19 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
VCVladimir N. Chubarev
Vladimir N. Chubarev
Narasimha BeerakaNarasimha Beeraka
Narasimha Beeraka
MSMikhail Sinelnikov
Mikhail Sinelnikov
КБКирилл Булыгин
Кирилл Булыгин
VNVladimir Nikolenko
Vladimir Nikolenko
Olga SukochevaOlga Sukocheva
Olga Sukocheva
It is with deep sadness that we offer our memorial on the unexpected demise of our dear colleague, Professor Gjumrakch Aliev

18 July 2020 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
DGDmitry Giller
Dmitry Giller
BGBoris Giller
Boris Giller
GSGalina Scherbakova
Galina Scherbakova
EMElizaveta Mikhaylenko
Elizaveta Mikhaylenko
LMLiudmila M. Mikhaleva
Liudmila M. Mikhaleva
Gjumrakch AlievGjumrakch Aliev
Gjumrakch Aliev
Background: Tracheal bifurcation resection remains the greatest challenge in airway reconstruction, especially with extensive lesions. Additionally, lung cancer and pulmonary tuberculosis comorbidity complicate the chemoradiotherapy treatment due to the TB reactivation. This case describes tracheal resection in a patient with both tuberculosis (TB) and lung cancer. Case presentation: The patient was diagnosed with right lung tuberculosis and upper lobe cancer with trachea invasion complicated by hemoptysis. A right pneumonectomy with circular trachea bifurcation resection was performed. Radiotherapy and chemotherapy were not administered to avoid TB reactivation. At 5.5 years post-surgery, there was cancer recurrence that was treated with radiation therapy. At 10 years post-surgery, an invasive squamous-cell carcinoma of a three-segment bronchus on the left was revealed. Radiation therapy and a course of chemotherapy were carried out with almost complete tumor regression. Conclusions: TB presence should not serve as a basis for the refusal of cancer treatment. Combined treatment may be recommended when the main infection focus in the pulmonary parenchyma is removed during surgery.

25 December 2023 in Antibiot Khimioter = Antibiotics and Chemotherapy
Verified
Journal Article
Open access
PDF file
SASherzod Pardaboevich Abdullaev
Sherzod Pardaboevich Abdullaev
КMК. М.-В. Mammaev
К. М.-В. Mammaev
NDNatalia Denisenko
Natalia Denisenko
ITI. L. Temirbulatov
I. L. Temirbulatov
AKA. А. Kachanova
A. А. Kachanova
DSDmitry Sychev
Dmitry Sychev
Background. Previously, genetic markers rs11385942 G>GA and rs657152 C>A of disease severity were identified for COVID-19. The study of the prevalence of clinically significant genetic markers may be useful for the development of region-specific approaches to disease control, considering, among other things, the ethnic composition of the territory, which is especially relevant for Russia. Based on the ethnic heterogeneity of the population of the Republic of Dagestan, this region was chosen as an example to study the distribution of COVID-19 severity markers of interest. Objective. Investigation of the prevalence of rs11385942 G>GA and rs657152 C>A markers among five ethnic groups residing in Dagestan. Methods. The study included 605 healthy volunteers (158 men and 447 women) from five different autochthonous ethnic groups living in the Republic of Dagestan: 118 Avars, 121 Dargins, 116 Laks, 127 Kumyks, and 123 Lezgins. Blood served as a material for determining polymorphisms. Carriage of polymorphic markers was determined by real-time polymerase chain reaction method. Results. The prevalence of rs11385942 G>GA marker ranges from 10.17% among Avars to 15.04% among Lezgins; significant differences were found in comparison with Russian ethnic group from literature sources. The second marker – rs657152 A>C — is distributed relatively homogeneously in the studied groups, without significant differences, and correlates with the data on the frequency of marker detection among Russians, as well as among European populations and worldwide — 50–60%. Conclusion. No differences were found within the ethnic groups of Dagestan in the carriage of both studied COVID-19 severity markers. At the same time, the rs11385942 G>GA marker detection frequency in the analyzed groups was on average higher in comparison with Russians and the average values for European populations.